Case reports show tirzepatide reduces alcohol consumption in patients with liver disease, suggesting a promising treatment option.
The interaction between alcohol consumption and metabolic risk factors in liver disease is bidirectional, necessitating concurrent improvement of both aspects. Treatment with tirzepatide for type 2 diabetes was associated with reduced alcohol consumption in our cases. Tirzepatide might represent an optimal therapeutic option for patients with alcohol-associated liver disease and type 2 diabetes given its potential to reduce alcohol consumption and ameliorate metabolic risk factors.
No takes yet. Share an insight, caveat, or question.
Takizawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: